在现实环境中治疗过敏性鼻炎的韩国医学注册表 (KOREA-R):一个多中心注册表协议
Boram Lee1, Gyu Tae Chang2, Hyelim Lee3
1Korea Institute of Oriental Medicine, Daejeon, Republic of Korea.
BMC complementary medicine and therapies
|July 22, 2025
概括
这项研究建立了针对过敏性鼻炎的韩国医学注册表 (KOREA-R),以收集有关草药的真实数据. 研究结果将揭示针对过敏性鼻炎的个性化韩国医学治疗的有效性,安全性和成本效益.
科学领域:
- 综合医学是一个整体的医学.
- 现实世界的证据.
- 临床研究 临床研究
背景情况:
- 过敏性鼻炎显著影响生活质量,并造成社会经济成本.
- 韩国医学,包括草药,是过敏性鼻炎的首选治疗方法.
- 在临床试验中,为草药制剂开发安慰剂是具有挑战性的.
研究的目的:
- 建立一个注册 (KOREA-R) 使用现实世界的数据 (RWD) 韩国医学治疗过敏性鼻炎.
- 在临床实践中评估草药的有效性,安全性和成本效益.
- 为过敏性鼻炎提供个性化治疗策略的数据.
主要方法:
- 在现实环境中治疗过敏性鼻炎的KOrean药物REgistry (KOREA-R) 将招收400名患者.
- 数据收集包括症状严重程度,生活质量,治疗细节,不良事件和12个月的实验室测试.
- 将采用诸如倾向性得分匹配和差异差异等统计分析.
主要成果:
- 将收集有关韩国医学治疗过敏性鼻炎的现实数据.
- 将分析草药的有效性,安全性和成本效益.
- 将产生个性化的治疗见解.
结论:
- 韩国-R的发现将阐明韩国医学对过敏性鼻炎的有效性和安全性,强调个性化的草药.
- 系统的RWD收集将为患者和决策者提供成本效益和成本效益的信息.
- 该注册表支持基于证据的韩国医学整合到过敏性鼻炎管理中.
相关概念视频
Allergic Reactions
28.7K
Overview
28.7K
Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
Allergic Drug Reactions
981
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
981
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
469
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
469
Asthma-II: Pathophysiology and Classification
2.9K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.9K
Asthma-III: Symptoms and Complications
2.6K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.6K


